Rett syndrome

Orphan designation: Adeno-associated viral vector serotype 9 containing the human MECP2 gene, an intron encoding a miRNA generating sequence, and complementary miRNA binding sites Treatment of Rett syndrome, 12/01/2024 Positive

Retrieved on: 
Thursday, April 18, 2024
MECP2, Patient, Committee, EMA, IRIS, Rett, Rett syndrome, COMP, European Commission, Marketing, Medicine, Pharmaceutical industry

Overview

Key Points: 
  • Overview
    This medicine was designated as an orphan medicine for treatment of the Rett syndrome on 12 January 2024.
  • Orphan designation does not mean the medicine is available or authorised for use.
  • All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, and Anavex and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, April 9, 2024
Psoriasis, Form, Patient, Defendant, News, IPO, Crohn's disease, Security (finance), Inflammation, Rett syndrome, Prospectus, Complaint, P.C, Clinical trial, MCI, Radar, File, Register, Pharmaceutical industry

The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

Key Points: 
  • The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.
  • For more information on the Anavex class action go to: https://bespc.com/cases/AVXL

SHAREHOLDER ALERT: Anavex Life Sciences Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

Retrieved on: 
Friday, April 5, 2024
Patient, Certification, Block & Leviton, Rett syndrome, Clinical trial, Cryptocurrency

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) for securities law violations.

Key Points: 
  • BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) for securities law violations.
  • Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses.
  • The study failed to show statistical significance towards its primary endpoints, causing shares of Anavex Life Sciences Corp. stock to drop approximately 35%.
  • Block & Leviton is widely regarded as one of the leading securities class action firms in the country.

Robbins LLP Reminds Investors to Seek Counsel in the Class Action Against Anavex Life Sciences Corporation (AVXL)

Retrieved on: 
Friday, April 5, 2024
Rett, Excellence, Central nervous system, Patient, SAN, CNS, Rett syndrome, Complaint, News, LLP, Person, Pharmaceutical industry

SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.

Key Points: 
  • SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • Anavex sponsored the “Excellence” Phase II/Phase III study to investigate blarcamesine as a treatment for pediatric Rett syndrome patients.
  • What Now: You may be eligible to participate in the class action against Anavex Life Sciences Corporation.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hut 8, Ventyx, and Anavex and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, April 5, 2024
Bitcoin, Research, Bankruptcy, Psoriasis, Register, Form, Patient, Defendant, News, IPO, Crohn's disease, Security (finance), Data mining, Inflammation, Rett syndrome, Prospectus, Complaint, Hut 8, P.C, Clinical trial, MCI, Radar, File, Mergers and acquisitions, Cryptocurrency

In November 2023, Hut 8 formed following the merger of Hut 8 Mining Corp. (“Legacy Hut”) and U.S. Data Mining Group, Inc. d/b/a US Bitcoin Corp. (“USBTC”) (the “Merger”).

Key Points: 
  • In November 2023, Hut 8 formed following the merger of Hut 8 Mining Corp. (“Legacy Hut”) and U.S. Data Mining Group, Inc. d/b/a US Bitcoin Corp. (“USBTC”) (the “Merger”).
  • USBTC held a 50% interest in a joint venture bitcoin mining facility, located in King Mountain, Texas (the “King Mountain JV”), which was acquired in the Merger.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Anavex class action go to: https://bespc.com/cases/AVXL

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders

Retrieved on: 
Thursday, April 4, 2024
Telephone, Patient, News, LLP, CLASS, Rett syndrome, Clinical trial, MCI, Radar, NEXT, COST, Court, Cryptocurrency

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Anavex Life Sciences investors who were adversely affected by alleged securities fraud between February 1, 2022 and January 1, 2024.
  • Follow the link below to get more information and be contacted by a member of our team:
    AVXL investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Thursday, April 4, 2024
Central nervous system, Patient, CNS, Research, Neurodevelopmental disorder, News, Avatar, Rett syndrome, Complaint, Fraud, Excellence, FDA, Central nervous system disease, Court, Person, Pharmaceutical industry

Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.

Key Points: 
  • Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Anavex you have until May 13, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Class Action Filed Against Anavex Life Sciences Corporation (AVXL) Seeking Recovery for Investors – Contact The Gross Law Firm

Retrieved on: 
Wednesday, April 3, 2024
Patient, News, Rett syndrome, Clinical trial, MCI, Radar, Fraud, NEXT, Security (finance)

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL).

Key Points: 
  • NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL).
  • Shareholders who purchased shares of AVXL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Anavex Life Sciences Corporation

Retrieved on: 
Monday, April 1, 2024
Central nervous system, District court, Patient, CNS, Research, Neurodevelopmental disorder, News, Avatar, Rett syndrome, Complaint, Action Replay, Excellence, FDA, Central nervous system disease, Court, Advertising

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points: 
  • NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
    Do you, or did you, own shares of Anavex Life Sciences Corporation (NASDAQ: AVXL)?
  • If you wish to serve as lead plaintiff, you must move the Court no later than May 13, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hut 8, Anavex, and Innoviz and Encourages Investors to Contact the Firm

Retrieved on: 
Sunday, March 31, 2024
Bitcoin, Research, Bankruptcy, Patient, Defendant, News, Data mining, Rett syndrome, Complaint, Hut 8, P.C, Clinical trial, MCI, Radar, Mergers and acquisitions, Cryptocurrency

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • Additional information about each case can be found at the link provided.
  • In November 2023, Hut 8 formed following the merger of Hut 8 Mining Corp. (“Legacy Hut”) and U.S. Data Mining Group, Inc. d/b/a US Bitcoin Corp. (“USBTC”) (the “Merger”).
  • For more information on the Innoviz class action go to: https://bespc.com/cases/INVZ